IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10682420 B1

PDFFull Text
Date of Patent:
Jun. 16, 2020

Filed:

May. 11, 2017

Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane

Applicant:

Abraxis Bioscience, Llc, Los Angeles, CA (US);

Inventors:

Neil P. Desai, Pacific Palisades, CA (US);

Patrick Soon-Shiong, Los Angeles, CA (US);

Assignee:

Abraxis BioScience, LLC, Summit, NJ (US);

Attorney:

Morrison & Foerster LLP

Primary Examiner:

Michael D Pak

Int. Cl.
CPC ...
A61K 38/38 (2006.01); A61K 47/64 (2017.01); A61K 31/704 (2006.01); A61K 31/7068 (2006.01); A61K 39/395 (2006.01); A61K 31/282 (2006.01); A61K 31/475 (2006.01); A61K 31/5377 (2006.01); A61K 31/513 (2006.01); A61K 31/664 (2006.01); A61K 9/00 (2006.01); A61K 9/51 (2006.01); A61K 47/42 (2017.01); A61P 35/00 (2006.01); A61K 31/337 (2006.01); A61K 31/505 (2006.01); A61K 31/661 (2006.01); A61K 31/7034 (2006.01);
U.S. Cl.
CPC ...
A61K 47/643 (2017.08); A61K 9/0019 (2013.01); A61K 9/5169 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/475 (2013.01); A61K 31/505 (2013.01); A61K 31/513 (2013.01); A61K 31/5377 (2013.01); A61K 31/661 (2013.01); A61K 31/664 (2013.01); A61K 31/704 (2013.01); A61K 31/7034 (2013.01); A61K 31/7068 (2013.01); A61K 39/39558 (2013.01); A61K 47/42 (2013.01); A61K 47/64 (2017.08); A61P 35/00 (2018.01);
Abstract

The present invention relates to methods and kits for the treatment of breast cancer based on hormone receptor status of progesterone receptor and estrogen receptor comprising the administration of a taxane alone, in combination with at least one other and other therapeutic agents, as well as other treatment modalities useful in the treatment of breast cancer. In particular, the invention relates to the use of nanoparticles comprising paclitaxel and albumin (such as Abraxane®) either alone or in combination with other chemotherapeutic agents or radiation, which may be used for the treatment of breast cancer which does not express estrogen receptor and/or progesterone receptor.

Find Patent Forward Citations

Loading…